Vulasala Sai Swarupa R, Sutphin Patrick D, Kethu Samira, Onteddu Nirmal K, Kalva Sanjeeva P
Department of Radiology, University of Florida College of Medicine, Jacksonville, FL, United States.
Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Front Oncol. 2023 May 30;13:963966. doi: 10.3389/fonc.2023.963966. eCollection 2023.
Colorectal malignancy is the third most common cancer and one of the prevalent causes of death globally. Around 20-25% of patients present with metastases at the time of diagnosis, and 50-60% of patients develop metastases in due course of the disease. Liver, followed by lung and lymph nodes, are the most common sites of colorectal cancer metastases. In such patients, the 5-year survival rate is approximately 19.2%. Although surgical resection is the primary mode of managing colorectal cancer metastases, only 10-25% of patients are competent for curative therapy. Hepatic insufficiency may be the aftermath of extensive surgical hepatectomy. Hence formal assessment of future liver remnant volume (FLR) is imperative prior to surgery to prevent hepatic failure. The evolution of minimally invasive interventional radiological techniques has enhanced the treatment algorithm of patients with colorectal cancer metastases. Studies have demonstrated that these techniques may address the limitations of curative resection, such as insufficient FLR, bi-lobar disease, and patients at higher risk for surgery. This review focuses on curative and palliative role through procedures including portal vein embolization, radioembolization, and ablation. Alongside, we deliberate various studies on conventional chemoembolization and chemoembolization with irinotecan-loaded drug-eluting beads. The radioembolization with Yttrium-90 microspheres has evolved as salvage therapy in surgically unresectable and chemo-resistant metastases.
结直肠癌是全球第三大常见癌症,也是主要的致死原因之一。约20%-25%的患者在确诊时已出现转移,50%-60%的患者在疾病进程中会发生转移。肝脏是结直肠癌转移最常见的部位,其次是肺和淋巴结。这类患者的5年生存率约为19.2%。虽然手术切除是治疗结直肠癌转移的主要方式,但只有10%-25%的患者适合进行根治性治疗。广泛的肝切除术后可能会导致肝功能不全。因此,术前对未来肝脏残余体积(FLR)进行正式评估对于预防肝衰竭至关重要。微创介入放射技术的发展改进了结直肠癌转移患者 的治疗方案。研究表明,这些技术可以解决根治性切除的局限性,如FLR不足、双叶病变以及手术风险较高的患者。本综述重点介绍了包括门静脉栓塞、放射性栓塞和消融在内的治疗方法的根治性和姑息性作用。此外,我们还探讨了关于传统化疗栓塞以及载有伊立替康的药物洗脱微球化疗栓塞的各种研究。用钇-90微球进行放射性栓塞已发展成为不可切除及化疗耐药转移瘤的挽救性治疗方法。